Key facts
- It has raised $43.1M; the latest was Later Stage VC ($13.8M) in May 2025.
- Notable investors include Fortune Capital, Guangdong Technology Financial Group, TopoScend Capital, GDD Industry Fund, Binhai Fund Management — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Accurate International
- ·The full record, as it builds
Funding rounds
No funding rounds for Accurate International are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Accurate International
Operator of a biomedical company designed for organoids. The company focuses on applying organoid technologies in the areas of tumor precision diagnosis and new drug research and development, committing to building the entire industry chain and technical standards of organoids and improving the effectiveness of disease diagnosis, treatment and prevention.
- Sector
- Healthcare
- HQ
- Guangzhou, China
- Founded
- 2018
- Employees
- 45
- Website
- bio-accurate.com/
- Ownership
- Privately Held (backing)
Accurate International doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Accurate International shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Accurate International in its N-PORT filings yet. We sweep new filings monthly.